Regulatory tracker: NICE, in reversal, endorses Pfizer's Talzenna
Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Be sure to come back regularly for …